Phospho-CrkL (Tyr207) Antibody

• 产品编号：CST-3181S      品牌：CST       原厂货号：3181S
• 产品分类：抗体 > 一抗 > 磷酸化抗体
• 应用分类：

描述：

Phospho-CrkL (Tyr207) 抗体只能检测内源的在tyr207位点磷酸化的CrkL蛋白。此抗体与在tyr221位点磷酸化的CrkII交叉反应。此多克隆抗体是通过合成人源对应的CrkL Tyr207位点周围的磷肽段来免疫动物而获得。抗体是通过protein A和多肽亲和层析纯化。CrkL, 一个39 kDa 接头蛋白, 对造血细胞有主要的调节功能。 CrkL有一个SH2 和两个SH3区域, 与 CrkII有60%的相似度(1)。CrkL N-末端的SH3域能够结合蛋白如C3G, SOS, PI3K, c-Abl 和 BCR/Abl。 CrkL的SH2区域能够结合到酪氨酸磷酸化的蛋白上如Cbl, HEF1, CAS 和 paxillin (2,3)。CrkL通过不同的细胞因子和生长因子起始并参与到各种信号级联反应中。Crk激活的信号转导的生物学功能包括调节细胞的粘连，细胞迁移和免疫细胞的应答(4)。在慢性粒细胞白血病中，CrkL是肿瘤蛋白 BCR/Abl一个突出的底物并能结合BCR/Abl和c-Abl (5)。CrkL在CML中性粒细胞和中主要且组成型的酪氨酸磷酸化，但是在正常的中性粒细胞中没有被磷酸化。此外, 用细胞因子及其竞争者刺激正常的中性粒细胞并不能诱导此蛋白的磷酸化(6)，这表明此蛋白可能是干预治疗的一个有用的靶点或者作为疾病的只要指示蛋白。CrkL 的Tyr207位点是BCR/Abl 磷酸化的位点(7)。

1. Satter, M. and Salgia, R. (1998) Leukemia 12, 637-644.
2. Feller, S. M. et al. (1998) J. Cell. Physiol. 177, 535-552.
3. Kiyokawa, E. et al. (1997) Crit. Rev. Oncog. 8, 329-342.
4. Feller, S. M. et al. (2001) Oncogene 20, 6348-6371.
5. Grumbach, I. M. et al. (2001) Br. J. Haematol. 112, 327-336.
6. Nicholas, G. L. et al. (1994) Blood 84, 2912-2918.
7. de Jong, R. et al. (1997) Oncogene 14, 507-513.

原厂资料：

Specificity / Sensitivity

Phospho-CrkL (Tyr207) Antibody detects endogenous levels of CrkL only when phosphorylated at tyrosine 207. The antibody cross-reacts with CrkII phosphorylated at tyrosine 221.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr207 of human CrkL. Antibodies are purified by protein A and peptide affinity chromatography.

Background

CrkL, a 39 kDa adaptor protein, has a key regulatory role in hematopoietic cells. CrkL has one SH2 and two SH3 domains, with 60% homology to CrkII (1). The amino-terminal SH3 domain of CrkL binds proteins such as C3G, SOS, PI3K, c-Abl and BCR/Abl. The SH2 domain of CrkL can bind to tyrosine-phosphorylated proteins such as Cbl, HEF1, CAS and paxillin (2,3). CrkL is involved in various signaling cascades initiated by different cytokines and growth factors. The biological outcomes of the Crk-activated signal transduction include the modulation of cell adhesion, cell migration and immune cell responses (4). CrkL is a prominent substrate of the BCR/Abl oncoprotein in chronic myelogenous leukemia and binds to both BCR/Abl and c-Abl (5). CrkL is prominently and constitutively tyrosine phosphorylated in CML neutrophils and is not phosphorylated in normal neutrophils. Moreover, stimulation of normal neutrophils with cytokines and agonists does not induce tyrosine phosphorylation of this protein (6), indicating that it may be a useful target for therapeutic intervention or as a disease marker. Tyr207 in CrkL is the BCR/Abl phosphorylation site (7).

1. Satter, M. and Salgia, R. (1998) Leukemia 12, 637-644.
2. Feller, S. M. et al. (1998) J. Cell. Physiol. 177, 535-552.
3. Kiyokawa, E. et al. (1997) Crit. Rev. Oncog. 8, 329-342.
4. Feller, S. M. et al. (2001) Oncogene 20, 6348-6371.
5. Grumbach, I. M. et al. (2001) Br. J. Haematol. 112, 327-336.
6. Nicholas, G. L. et al. (1994) Blood 84, 2912-2918.
7. de Jong, R. et al. (1997) Oncogene 14, 507-513.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.